Sudeep Pharma’s initial public offering opened to a solid start on November 21, with the issue getting fully subscribed on the first day itself. The Vadodara-based ingredient manufacturer is looking to raise ₹895 crore through the offer, which includes a fresh issue of ₹95 crore and an offer-for-sale of around ₹800 crore by existing shareholders.
Retail and non-institutional investors drove most of the early demand, helping the issue cross 100% subscription quickly. Participation from qualified institutional buyers was comparatively slower but is expected to build as the issue progresses until it closes on November 25.
The grey market premium remained steady at ₹110–₹130, indicating that the stock could list 18–20% above the upper price band of ₹593 if current sentiment holds. Market watchers estimate a possible listing range of ₹700–₹715 based on prevailing trends.
Sudeep Pharma manufactures excipients and mineral-based ingredients used across the pharmaceutical, food, nutraceutical and personal care industries. The company plans to use its fresh capital mainly for machinery purchases at its Gujarat facility and for general corporate requirements.
Analyst views remain mixed. Some brokerages highlight the company’s wide product portfolio, established client base and steady financial performance as positives. Others point out that the IPO’s valuation appears elevated compared to peers, making it more favorable for long-term investors rather than those focused on immediate gains.
With a strong Day-1 performance supported by retail enthusiasm and a healthy grey market premium, investors will now be watching how institutional interest shapes up as the issue continues through the remaining subscription period.
Also Read: Groww Q2 profit up 12% despite revenue dip